Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy

Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy

Objective There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. However, in patients with advanced ICC, the safety and effi...

Full description

Bibliographic Details
Main Authors: Min Deng, Shaohua Li, Qiaoxuan Wang, Rongce Zhao, Jingwen Zou, Wenping Lin, Jie Mei, Wei Wei, Rongping Guo
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Annals of Medicine
Subjects:
Intrahepatic cholangiocarcinoma
immunotherapy
PD-1
real-world
outcome
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2022.2048416

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2022.2048416

Similar Items